A Study to Evaluate the Drug Interaction of ASP015K and Tacrolimus

A Phase 1, Open Label, Drug Interaction Study of the Pharmacokinetics of ASP015K and Tacrolimus After Separate and Concomitant Administration to Healthy Adult Subjects

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01190670

Enrollment

Registered

2010-08-30

Start date

2010-07-31

Completion date

2010-09-30

Last updated

2010-10-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy, Pharmacokinetics of ASP015K and Tacrolimus

Keywords

ASP015K, tacrolimus, healthy volunteers

Brief summary

The objective of the study is to characterize the effect of multiple doses of ASP015K on the pharmacokinetics of a single oral dose or a single intravenous (IV) dose of tacrolimus.

Detailed description

This is a 2-part study. Part 1 is a 2-sequence, drug interaction study to determine the effect of two different ASP015K doses on the pharmacokinetics of oral tacrolimus. Part 2 is a 1-sequence drug interaction study to determine the effect of the higher dose ASP015K on the pharmacokinetics of IV tacrolimus.

Interventions

DRUGTacrolimus

Oral and Intravenous

DRUGASP015K

Oral

Study design

Allocation

RANDOMIZED

Intervention model

CROSSOVER

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 55 Years

Healthy volunteers

Yes

Inclusion criteria

* Subject weighing at least 45kg and body mass index (BMI) of 18-32 kg/m2, inclusive * If female, subject is at least 2 years post menopausal or is surgically sterile per documentation provided by a third party medical professional and the subject is not pregnant as documented by a negative serum pregnancy test * If male, subject agrees to sexual abstinence, is surgically sterile, or is using a medically acceptable method to prevent pregnancy during the study period * 12-lead ECG is normal or if abnormal, the abnormality is not clinically significant * Clinical laboratory test results are within normal limits or not clinically significant * Medically healthy, with no clinically significant medical history or abnormalities

Exclusion criteria

* History of any clinically significant disorder, disease or malignancy excluding non-melanoma skin cancer * Recent history (within 6 months) of drug or alcohol abuse or positive urine screen for drugs of abuse/illegal drugs * Treatment with prescription drugs or complementary and alternative medicines (CAM) within 14 days prior to study drug administration, or over the counter medication within 1 week prior to study drug administration * A symptomatic, viral, bacterial or fungal infection within 1 week prior to clinic check-in * Positive test for hepatitis C antibody, or positive test for hepatitis B surface antigen (HBsAg) * History of human immunodeficiency virus (HIV) antibody * Positive tuberculosis (TB) skin test or Quantiferon Gold test * Vaccinated within the last 30 days prior to study drug administration * Received an experimental agent within 30 days or five half-lives, whichever is longer, prior to study drug administration * Any significant blood loss, donated one unit (450 mL) of blood or more, or received a transfusion of any blood or blood products within 60 days or donated plasma within 7 days prior to clinic admission * Absolute neutrophil count (ANC) \<2500 cells/mm3

Design outcomes

Primary

Measure	Time frame
Pharmacokinetic variables assessment through analysis of blood and urine samples	Days 1-13 and Days 26-33 (Part 1 only) sampled daily

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026